机构：[1]Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China[2]Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China[3]Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[4]Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China中山大学附属第一医院[5]Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[6]Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[7]Department of Breast Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China中山大学附属第二医院
第一作者机构：[1]Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
推荐引用方式(GB/T 7714)：
Jiang Zefei,Yu Zhigang,Geng Cuizhi,et al.Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Jiang, Zefei,Yu, Zhigang,Geng, Cuizhi,Lin, Ying,Liu, Zhenzhen...&Liu, Qiang.(2023).Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Jiang, Zefei,et al."Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学